Prestige Consumer Healthcare Inc. PBH
We take great care to ensure that the data presented and summarized in this overview for Prestige Consumer Healthcare Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PBH
View all-
Black Rock Inc. New York, NY8.28MShares$497 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.49MShares$330 Million0.01% of portfolio
-
Ariel Investments, LLC Chicago, IL3.59MShares$216 Million2.75% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.59MShares$156 Million0.04% of portfolio
-
Kayne Anderson Rudnick Investment Management LLC Los Angeles, CA2.21MShares$133 Million0.35% of portfolio
-
State Street Corp Boston, MA1.96MShares$118 Million0.0% of portfolio
-
Macquarie Group LTD Australia, C31.62MShares$97.3 Million0.12% of portfolio
-
Allspring Global Investments Holdings, LLC1.59MShares$95.6 Million0.18% of portfolio
-
Geode Capital Management, LLC Boston, MA1.44MShares$86.3 Million0.01% of portfolio
-
Westwood Holdings Group Inc Dallas, TX1.14MShares$68.5 Million0.55% of portfolio
Latest Institutional Activity in PBH
Top Purchases
Top Sells
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
Insider Transactions at PBH
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2025
|
Jeffrey Zerillo Senior VP Operations |
SELL
Open market or private sale
|
Direct |
281
-0.66%
|
$16,860
$60.0 P/Share
|
|
Nov 28
2025
|
Jeffrey Zerillo Senior VP Operations |
SELL
Open market or private sale
|
Direct |
719
-1.67%
|
$43,140
$60.0 P/Share
|
|
Nov 25
2025
|
John E Byom Director |
SELL
Open market or private sale
|
Direct |
3,000
-5.5%
|
$177,000
$59.35 P/Share
|
|
Aug 05
2025
|
John F. Kelly Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+30.15%
|
-
|
|
Aug 05
2025
|
John E Byom Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+3.69%
|
-
|
|
Aug 05
2025
|
Celeste A. Clark Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+13.4%
|
-
|
|
Aug 05
2025
|
James D Arecca Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+24.11%
|
-
|
|
Aug 05
2025
|
Sheila Hopkins Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+6.5%
|
-
|
|
Aug 05
2025
|
Dawn M. Zier Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,094
+11.24%
|
-
|
|
May 07
2025
|
Adel Mekhail EVP, Marketing & Sales |
SELL
Payment of exercise price or tax liability
|
Direct |
457
-2.14%
|
$37,017
$81.41 P/Share
|
|
May 07
2025
|
Ronald M. Lombardi Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,305
-0.66%
|
$186,705
$81.41 P/Share
|
|
May 07
2025
|
Jeffrey Zerillo Senior VP Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
354
-0.82%
|
$28,674
$81.41 P/Share
|
|
May 07
2025
|
Mary Beth Fritz SVP Quality & Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
315
-1.81%
|
$25,515
$81.41 P/Share
|
|
May 05
2025
|
Ronald M. Lombardi Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
52,256
+6.75%
|
-
|
|
May 05
2025
|
Adel Mekhail EVP, Marketing & Sales |
BUY
Grant, award, or other acquisition
|
Direct |
5,086
+10.98%
|
-
|
|
May 05
2025
|
William P'Pool Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,271
+10.67%
|
-
|
|
May 05
2025
|
Christine Sacco CFO & COO |
BUY
Grant, award, or other acquisition
|
Direct |
12,702
+9.96%
|
-
|
|
May 05
2025
|
Jeffrey Zerillo Senior VP Operations |
BUY
Grant, award, or other acquisition
|
Direct |
3,562
+3.98%
|
-
|
|
May 05
2025
|
Ronald M. Lombardi Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
19,294
-5.42%
|
$1,582,108
$82.98 P/Share
|
|
May 05
2025
|
Mary Beth Fritz SVP Quality & Regulatory |
SELL
Payment of exercise price or tax liability
|
Direct |
741
-4.09%
|
$60,762
$82.98 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 93K shares |
|---|---|
| Exercise of conversion of derivative security | 17.4K shares |
| Open market or private sale | 23.1K shares |
|---|---|
| Payment of exercise price or tax liability | 39.9K shares |